Entero TherapeuticsENTO
About: Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Employees: 11
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
13% more funds holding
Funds holding: 8 [Q2] → 9 (+1) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
3.5% less ownership
Funds ownership: 5.39% [Q2] → 1.88% (-3.5%) [Q3]
88% less capital invested
Capital invested by funds: $183K [Q2] → $21.1K (-$162K) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for ENTO.
Financial journalist opinion
Based on 8 articles about ENTO published over the past 30 days
